The future of 340B in rural America — What providers need to know to protect the health of their communities
During the summer of 2020, a handful of major drugmakers caused upheaval in the pharmaceutical industry when they announced changes to their participation in the 340B Drug Pricing Program, eliciting condemnation from providers and their allies.
The announced changes primarily affect contract pharmacies, which play a unique role for providers and patients in rural communities where healthcare access is already a significant issue. While drugmakers' concerns about compliance challenges at contract pharmacies are not unfounded, the actions may produce harmful results for vulnerable patients and the health of rural communities.
The announced changes primarily affect contract pharmacies, which play a unique role for providers and patients in rural communities where healthcare access is already a significant issue. While drugmakers' concerns about compliance challenges at contract pharmacies are not unfounded, the actions may produce harmful results for vulnerable patients and the health of rural communities.
This report includes:
- A timeline of recent 340B developments
- An overview of the role of contract pharmacies in 340B
- A look at the potential consequences cutting out contract pharmacies could have on rural communities
Please fill out the form to download the whitepaper.